Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025)
Zentalis Pharmaceuticals (ZNTL) recorded quarterly Return on Sales of 0.06% in Q3 2025, up 8.27% quarter-over-quarter from 0.06% in Q2 2025, and down 1.0% on a YoY basis from 0.06% in Q3 2024.
Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025) Analysis & Trends
Zentalis Pharmaceuticals' Return on Sales history runs 2 years deep, the most recent figure standing at 0.06% for Q3 2025.
- In Q3 2025, Return on Sales fell 1.0% year-over-year to 0.06%; the TTM figure through Sep 2025 stood at 0.06% (down 1.0% YoY), while the FY2024 annual figure was 0.02%, changed N/A from the prior year.
- Return on Sales was 0.06% for Q3 2025 at Zentalis Pharmaceuticals, up from 0.06% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2024 to a low of 0.08% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.00% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 0.00% |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Zentalis Pharmaceuticals | 253.30 Mn | 253.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.06% |
| Jun 30, 2025 | -0.06% |
| Mar 31, 2025 | -0.08% |
| Dec 31, 2024 | -0.02% |
| Sep 30, 2024 | -0.04% |
| Jun 30, 2024 | -0.05% |
| Mar 31, 2024 | 0.00% |